How to secure your access to the next big market opportunity - Saudi Arabia

Saudi Arabia's Vision 2030 is an ambitious plan to diversify the national economy, promote social reform, and transform the country into a global investment hub.

Pharmaceutical development, assessment, and reimbursement is a centerpiece of the Vision 2030 plan; a Central Health Technology Assessment (HTA) is being established under the Ministry of Health to fulfill the promise. This new HTA framework will provide evidence-based recommendations to guide policy decisions on the pricing, reimbursement, and adoption of health technologies.

Why Saudi Arabia?

It is a market for pharmaceutical products today which promises the following at global launch:

Pricing parity to the USA
Open product access to their entire population
An early win in the global launch sequence

Contact us

Download the one-pager

The implications for pharmaceutical development and commercial
launch are huge

2X

Saudi Arabia has a population of 36.41 million. By 2050, the population is expected to reach 77.2 million people.

1.6M

With a population growth rate of approximately 1.43%, Saudi Arabia sees an annual increase of 1.6 million people.

76 years

Saudi Arabia has a population of 36.41 million. By 2050, the population is expected to reach 77.2 million people.

We are committed to supporting the commercialisation of products that make a difference in people’s lives. We work across a product’s lifecycle, to support pharma, med tech and biotech companies around the world.

Pricing

Saudi Arabia offers the potential for pricing similar to the United States, making it a lucrative market for launching new therapies. The alignment with global pricing standards enhances the attractiveness of entering this market.

Open Access to a Large Market

With 36 million people and no copayments or restrictions, Saudi Arabia allows pharmaceutical companies broad patient access. This facilitates faster adoption and market penetration for new products.

Early Launch Sequence

Saudi Arabia’s healthcare reforms support early market entry for new drugs, offering a chance for companies to establish a presence early in the product commercial life cycle - ahead of competitors and securing a first-mover advantage.

Focus on Generic Medicines and Local Manufacturing

The government's push for generics and local manufacturing reduces import dependency and enhances drug security, providing an opportunity for companies that align with these goals.

Policy Recommendations and Health Innovation

Companies that align with Saudi health policies, particularly in oncology and pricing, will find favorable conditions for market access. The emphasis on innovation also supports the introduction of new health technologies.

Methodology of
The Saudi Arabia HTA process

The methodology incorporates elements from HTA processes in the UK (NICE), Sweden (TLV), and Canada (CADTH), including:

Canadian Agency for Drugs and Technologies in Health (CADTH)

Establishment of an explicit cost-effectiveness threshold to guide funding decisions, based on the marginal cost per quality-adjusted life year (QALY) gained.
Consideration of disease severity, unmet medical need, and societal impact in addition to cost-effectiveness.

The Tandvårds-läkemedelsverket (TLV)

Establishment of an explicit cost-effectiveness threshold to guide funding decisions, based on the marginal cost per quality-adjusted life year (QALY) gained.
Consideration of disease severity, unmet medical need, and societal impact in addition to cost-effectiveness.

National Institute for Health and Care Excellence (NICE)

Systematic review and critical appraisal of clinical evidence on the safety, efficacy, and effectiveness of health technologies.
Economic evaluation, including cost-effectiveness and cost-utility analyses, to assess value for money.

FIECON + Pharma BP collaborate to deliver HTA excellence in Saudi Arabia

FIECON has partnered with Pharma BP, a leading life sciences consultancy with specialty expertise in the Middle East and Africa (MEA) region and a trailblazer in the evolving regional landscape.

Together, our expertise bridges the gap between technical excellence and practical solutions in HEOR, market access, and HTA. With an impressive 96% success rate across more than 75 global HTA submissions and a perfect 100% success rate in rare disease HTA submissions,

FIECON consistently delivers results that matter.FIECON can offer comprehensive HTA support services, including:

Pricing: Assistance with strategic pricing decisions.
Economic Modelling: Development of economic models to assess cost-effectiveness.
HTA Strategy: Formulation of strategies for successful HTA submissions.
Submission Dossier: Preparation of detailed submission dossiers.
Post-Submission Negotiations: Support during negotiations after the submission process.

About Pharma BP

Pharma BP is a consulting and market research firm focusing on the life sciences sector within the MEA region. Based in Dubai, Pharma BP support the clients in defining how to get to market successfully in MEA region, with the broadest access and at commercially sustainable price points.

Lavni Varyani

Founding Partner at Pharma BP

email@domain.com

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.

Brainstorm solutions to key challenges with experienced team
Validate your strategy and value evidence
Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Thank you!

We received your details. Someone from our team will contact you soon.

Oops!

Something went wrong while submitting the form.